NCT02236169View on ClinicalTrials.gov

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

April 30, 2001

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Ipratropium bromide HFA-134a inhalation aerosol

DRUG

Atrovent CFC inhalation aerosol

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY